CAYMAN CHEMICAL COMPANY Non-Antibody Products — page 745 of 870
Non-Antibody Products
Page 745 of 870
| Name | Description | Size | Catalog # | |
|---|---|---|---|---|
| SHA-68 | An NPSR antagonist (IC50s = 22 and 23.8 nM for the NPSR Asn107 and NPSR Il… | 5 mg | 21512-5 | More Info |
| Shanzhiside methyl ester | An iridoid glycoside with anti-inflammatory and antinociceptive activities… | 1 mg | 34047-1 | More Info |
| Shanzhiside methyl ester | An iridoid glycoside with anti-inflammatory and antinociceptive activities… | 10 mg | 34047-10 | More Info |
| Shanzhiside methyl ester | An iridoid glycoside with anti-inflammatory and antinociceptive activities… | 25 mg | 34047-25 | More Info |
| Shanzhiside methyl ester | An iridoid glycoside with anti-inflammatory and antinociceptive activities… | 5 mg | 34047-5 | More Info |
| 14(S)-HDHA | An oxygenation product of DHA; formed by 12-LO or 15-LO processing of DHA;… | 100 µg | 15253-100 | More Info |
| 14(S)-HDHA | An oxygenation product of DHA; formed by 12-LO or 15-LO processing of DHA;… | 25 µg | 15253-25 | More Info |
| 14(S)-HDHA | An oxygenation product of DHA; formed by 12-LO or 15-LO processing of DHA;… | 50 µg | 15253-50 | More Info |
| 17(S)-HDHA | A hydroxy fatty acid formed from DHA by 15-LO and is a precursor to 17(S)-… | 100 µg | 10009799-100 | More Info |
| 17(S)-HDHA | A hydroxy fatty acid formed from DHA by 15-LO and is a precursor to 17(S)-… | 25 µg | 10009799-25 | More Info |
| 17(S)-HDHA | A hydroxy fatty acid formed from DHA by 15-LO and is a precursor to 17(S)-… | 250 µg | 10009799-250 | More Info |
| 17(S)-HDHA | A hydroxy fatty acid formed from DHA by 15-LO and is a precursor to 17(S)-… | 50 µg | 10009799-50 | More Info |
| 17(S)-HDHA-d5 | An internal standard for the quantification of 17(S)-HDHA by GC- or LC-MS | 100 µg | 29797-100 | More Info |
| 17(S)-HDHA-d5 | An internal standard for the quantification of 17(S)-HDHA by GC- or LC-MS | 25 µg | 29797-25 | More Info |
| 17(S)-HDHA-d5 | An internal standard for the quantification of 17(S)-HDHA by GC- or LC-MS | 50 µg | 29797-50 | More Info |
| 14(S)-HDHA-d5 | An internal standard for the quantification of 14(S)-HDHA by GC- or LC-MS,, | 100 µg | 9002764-100 | More Info |
| 14(S)-HDHA-d5 | An internal standard for the quantification of 14(S)-HDHA by GC- or LC-MS,, | 25 µg | 9002764-25 | More Info |
| 14(S)-HDHA-d5 | An internal standard for the quantification of 14(S)-HDHA by GC- or LC-MS,, | 50 µg | 9002764-50 | More Info |
| 17(S)-HDHA-d5 ethyl ester | An internal standard for the quantification of 17-HDHA ethyl ester by GC-… | 25 µg | 30577-25 | More Info |
| 17(S)-HDHA-d5 ethyl ester | An internal standard for the quantification of 17-HDHA ethyl ester by GC-… | 50 µg | 30577-50 | More Info |
| 17(S)-HDoTE | A metabolite of adrenic acid | 100 µg | 34745-100 | More Info |
| 17(S)-HDoTE | A metabolite of adrenic acid | 25 µg | 34745-25 | More Info |
| 17(S)-HDoTE | A metabolite of adrenic acid | 50 µg | 34745-50 | More Info |
| 11(S)-HEDE | 11(S)-HEDE is isolated by the chromatographic resolution of (±)11-H… | 100 µg | 37510-100 | More Info |
| 11(S)-HEDE | 11(S)-HEDE is isolated by the chromatographic resolution of (±)11-H… | 25 µg | 37510-25 | More Info |
| 11(S)-HEDE | 11(S)-HEDE is isolated by the chromatographic resolution of (±)11-H… | 250 µg | 37510-250 | More Info |
| 11(S)-HEDE | 11(S)-HEDE is isolated by the chromatographic resolution of (±)11-H… | 50 µg | 37510-50 | More Info |
| 15(S)-HEDE | 15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HED… | 100 µg | 37720-100 | More Info |
| 15(S)-HEDE | 15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HED… | 25 µg | 37720-25 | More Info |
| 15(S)-HEDE | 15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HED… | 250 µg | 37720-250 | More Info |
| 15(S)-HEDE | 15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HED… | 50 µg | 37720-50 | More Info |
| 11(S)-HEPE | 11(S)-HEPE is a monohydroxy fatty acid derived from EPA, theoretically by… | 100 µg | 32510-100 | More Info |
| 11(S)-HEPE | 11(S)-HEPE is a monohydroxy fatty acid derived from EPA, theoretically by… | 25 µg | 32510-25 | More Info |
| 11(S)-HEPE | 11(S)-HEPE is a monohydroxy fatty acid derived from EPA, theoretically by… | 50 µg | 32510-50 | More Info |
| 12(S)-HEPE | 12(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action… | 100 µg | 32550-100 | More Info |
| 12(S)-HEPE | 12(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action… | 25 µg | 32550-25 | More Info |
| 12(S)-HEPE | 12(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action… | 50 µg | 32550-50 | More Info |
| 15(S)-HEPE | A monohydroxy fatty acid derived from EPA; serum levels are elevated in pa… | 100 µg | 32710-100 | More Info |
| 15(S)-HEPE | A monohydroxy fatty acid derived from EPA; serum levels are elevated in pa… | 25 µg | 32710-25 | More Info |
| 15(S)-HEPE | A monohydroxy fatty acid derived from EPA; serum levels are elevated in pa… | 250 µg | 32710-250 | More Info |
| 15(S)-HEPE | A monohydroxy fatty acid derived from EPA; serum levels are elevated in pa… | 50 µg | 32710-50 | More Info |
| 5(S)-HEPE | An active metabolite of EPA; an agonist of GPR119; increases cAMP accumula… | 100 µg | 32210-100 | More Info |
| 5(S)-HEPE | An active metabolite of EPA; an agonist of GPR119; increases cAMP accumula… | 25 µg | 32210-25 | More Info |
| 5(S)-HEPE | An active metabolite of EPA; an agonist of GPR119; increases cAMP accumula… | 250 µg | 32210-250 | More Info |
| 5(S)-HEPE | An active metabolite of EPA; an agonist of GPR119; increases cAMP accumula… | 50 µg | 32210-50 | More Info |
| 8(S)-HEPE | 8(S)-HEPE is a monohydroxy fatty acid produced by lipoxygenase oxidation o… | 100 µg | 32350-100 | More Info |
| 8(S)-HEPE | 8(S)-HEPE is a monohydroxy fatty acid produced by lipoxygenase oxidation o… | 25 µg | 32350-25 | More Info |
| 8(S)-HEPE | 8(S)-HEPE is a monohydroxy fatty acid produced by lipoxygenase oxidation o… | 50 µg | 32350-50 | More Info |
| 9(S)-HEPE | A metabolite of EPA | 100 µg | 32410-100 | More Info |
| 9(S)-HEPE | A metabolite of EPA | 25 µg | 32410-25 | More Info |
| 9(S)-HEPE | A metabolite of EPA | 50 µg | 32410-50 | More Info |
| 15(S)-HEPE-d5 | An internal standard for the quantification of 15-HEPE by GC- or LC-MS | 100 µg | 31221-100 | More Info |
| 15(S)-HEPE-d5 | An internal standard for the quantification of 15-HEPE by GC- or LC-MS | 25 µg | 31221-25 | More Info |
| 15(S)-HEPE-d5 | An internal standard for the quantification of 15-HEPE by GC- or LC-MS | 50 µg | 31221-50 | More Info |
| 15(S)-HEPE-d5 ethyl ester | An internal standard for the quantification of 15-HEPE by GC- or LC-MS | 25 µg | 33783-25 | More Info |
| 15(S)-HEPE-d5 ethyl ester | An internal standard for the quantification of 15-HEPE by GC- or LC-MS | 50 µg | 33783-50 | More Info |
| Shepherdin (trifluoroacetate salt) | An inhibitor of the survivin-Hsp90 interaction; binds to the N-terminal do… | 1 mg | 38327-1 | More Info |
| Shepherdin (trifluoroacetate salt) | An inhibitor of the survivin-Hsp90 interaction; binds to the N-terminal do… | 10 mg | 38327-10 | More Info |
| Shepherdin (trifluoroacetate salt) | An inhibitor of the survivin-Hsp90 interaction; binds to the N-terminal do… | 25 mg | 38327-25 | More Info |
| Shepherdin (trifluoroacetate salt) | An inhibitor of the survivin-Hsp90 interaction; binds to the N-terminal do… | 5 mg | 38327-5 | More Info |
| 11(S)-HETE | A non-enzymatically derived oxylipin; serum levels decrease in patients wi… | 100 µg | 34510-100 | More Info |
| 11(S)-HETE | A non-enzymatically derived oxylipin; serum levels decrease in patients wi… | 25 µg | 34510-25 | More Info |
| 11(S)-HETE | A non-enzymatically derived oxylipin; serum levels decrease in patients wi… | 50 µg | 34510-50 | More Info |
| 12(S)-HETE | The predominant LO product of arachidonic acid formed in mammalian platele… | 100 µg | 34570-100 | More Info |
| 12(S)-HETE | The predominant LO product of arachidonic acid formed in mammalian platele… | 25 µg | 34570-25 | More Info |
| 12(S)-HETE | The predominant LO product of arachidonic acid formed in mammalian platele… | 50 µg | 34570-50 | More Info |
| 15(S)-HETE | An active metabolite of arachidonic acid; inhibits proliferation of HT-29… | 100 µg | 34720-100 | More Info |
| 15(S)-HETE | An active metabolite of arachidonic acid; inhibits proliferation of HT-29… | 25 µg | 34720-25 | More Info |
| 15(S)-HETE | An active metabolite of arachidonic acid; inhibits proliferation of HT-29… | 50 µg | 34720-50 | More Info |
| 15(S)-HETE | An active metabolite of arachidonic acid; inhibits proliferation of HT-29… | 500 µg | 34720-500 | More Info |
| 16(S)-HETE | An inhibitor of proximal tubule ATPase activity; a minor CYP450 metabolite… | 100 µg | 10004384-100 | More Info |
| 16(S)-HETE | An inhibitor of proximal tubule ATPase activity; a minor CYP450 metabolite… | 25 µg | 10004384-25 | More Info |
| 16(S)-HETE | An inhibitor of proximal tubule ATPase activity; a minor CYP450 metabolite… | 50 µg | 10004384-50 | More Info |
| 17(S)-HETE | A potent inhibitor of proximal tubule ATPase activity; is a CYP450 metabol… | 100 µg | 10011305-100 | More Info |
| 17(S)-HETE | A potent inhibitor of proximal tubule ATPase activity; is a CYP450 metabol… | 25 µg | 10011305-25 | More Info |
CAYMAN CHEMICAL COMPANY
CAYMAN CHEMICAL COMPANY
1180 East Ellsworth Road
Ann Arbor MI 48108
P: (734) 971-3335
P: (800) 364-9897 (USA & Canada only)
F: (734) 971-3640
Customer Service: custserv@caymanchem.com
Technical Support: techserv@caymanchem.com
Sales: sales@caymanchem.com
http://www.caymanchem.com
Return to Profile